No Data
No Data
Express News | EF Hutton Initiates Coverage On Can Fite Biofarma With Buy Rating, Announces Price Target of $10
Can Fite Biofarma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 167.38% EF Hutton → $10 Initiates Coverage On → Buy 05/09/2024 381.28% HC Wainwright & Co. $18
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and
Can-Fite BioPharma Shareholders Approve Key Proposals
Improvement in Patient With Decompensated Liver Cirrhosis Upon Treatment With Namodenoson
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
No Data